Samsung Bioepis agrees deal with J&J on Stelara biosimilar candidate

South Korea’s Samsung Bioepis is the latest to reach an agreement for a biosimilar of Stelara (ustekinumab).

The company said today that it has signed a settlement and license agreement with US healthcare giant Johnson & Johnson (NYSE: JNJ) settling all pending US patent litigation between the two companies and clearing the way for commercialization of Samsung Bioepis’ SB17, a proposed Stelara biosimilar in the USA. The license period will begin on February 22, 2025. The other terms of the agreement are confidential.

“We welcome this agreement which clears the way for SB17 in the US, which has a potential to broaden access to treatment for patients suffering inflammatory conditions,” said Kris Soyoung Lee, vice president and commercial team leader, at Samsung Bioepis. “Through our continuous innovations in product development and an uncompromising commitment to quality, we remain dedicated to advancing and expanding our biosimilar portfolio, so that more patients and healthcare systems across the world may benefit from biosimilars,” she added.